Lung Cancer

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the response of immunotherapy in patients with lung cancer.

Icotinib (Conmana) was associated with a 3.3-month increase in median progression-free survival compared with chemotherapy in patients with stage IIIB/IV non–small cell lung cancer.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Pembrolizumab induced an overall response rate of 33% in patients with extensive-stage small cell lung cancer.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Christine M. Lovly, MD, PhD, discusses the importance of identifying and targeting RET in non-small cell lung cancer.

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Nintedanib, an angiogenesis inhibitor, is being investigated as a first-line treatment for patients with unresectable malignant pleural mesothelioma (MPM).

Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.

Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.

ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.